Close Menu

NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

Evogene said that it plans to offer 5 million shares of its common stock at a proposed maximum offering price of $17.16 per share. If the underwriters on the offering exercise their overallotment option, that figure would rise to $90 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.

Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.

In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.